Omalizumab
XOLAIR, Xolair PFS
Anti-IgE
NADAC/unit
N/A
No Shortage
Tier 1: 124.3%
PA Req: 692.1%
XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a pe....
Market Intelligence
2025-08-13 Class II Recall: Cardinal Health Inc.
2025-08-13 Class II Recall: Cardinal Health Inc.
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.